

Marieke Krol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5340469/publications.pdf>

Version: 2024-02-01

29
papers

1,384
citations

471509

17
h-index

501196

28
g-index

31
all docs

31
docs citations

31
times ranked

2105
citing authors

#	ARTICLE	IF	CITATIONS
1	The iMTA Productivity Cost Questionnaire. <i>Value in Health</i> , 2015, 18, 753-758.	0.3	298
2	Productivity Costs in Economic Evaluations: Past, Present, Future. <i>Pharmacoeconomics</i> , 2013, 31, 537-549.	3.3	162
3	How to Estimate Productivity Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 2014, 32, 335-344.	3.3	144
4	Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies. <i>Pharmacoeconomics</i> , 2015, 33, 123-135.	3.3	112
5	Do Productivity Costs Matter?. <i>Pharmacoeconomics</i> , 2011, 29, 601-619.	3.3	102
6	Costs, quality of life, treatment satisfaction and compliance in patients with β^2 -thalassemia major undergoing iron chelation therapy: the ITHACA study. <i>Current Medical Research and Opinion</i> , 2008, 24, 1905-1917.	1.9	101
7	Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effects. <i>Social Science and Medicine</i> , 2012, 75, 1981-1988.	3.8	44
8	Concerns, quality of life, access to care and productivity of the general population during the first 8 weeks of the coronavirus lockdown in Belgium and the Netherlands. <i>BMC Health Services Research</i> , 2021, 21, 227.	2.2	44
9	Unpaid work in health economic evaluations. <i>Social Science and Medicine</i> , 2015, 144, 127-137.	3.8	42
10	In or Out? Income Losses in Health State Valuations: A Review. <i>Value in Health</i> , 2010, 13, 298-305.	0.3	41
11	A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. <i>European Journal of Health Economics</i> , 2016, 17, 391-402.	2.8	39
12	Productivity Costs in Health-State Valuations. <i>Pharmacoeconomics</i> , 2006, 24, 401-414.	3.3	28
13	The Impact of Patients' Subjective Life Expectancy on Time Tradeoff Valuations. <i>Medical Decision Making</i> , 2013, 33, 261-270.	2.4	26
14	Does the EQ-5D Reflect Lost Earnings?. <i>Pharmacoeconomics</i> , 2012, 30, 47-61.	3.3	25
15	Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699.	0.3	21
16	A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1313-1328.	1.8	19
17	Economic evaluations in European reimbursement submission guidelines: current status and comparisons. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 579-595.	1.4	19
18	Predicting productivity based on EQ-5D: an explorative study. <i>European Journal of Health Economics</i> , 2014, 15, 465-475.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises. <i>Value in Health</i> , 2009, 12, 172-180.	0.3	14
20	Exploring a new method for deriving the monetary value of a QALY. <i>European Journal of Health Economics</i> , 2016, 17, 801-809.	2.8	12
21	Patient adherence to subcutaneous IFN beta-1a injections using the RebiSmart^{®®} injection device: a retrospective real-world study among Dutch and German patients with multiple sclerosis. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1189-1196.	1.8	12
22	Altruistic Preferences in Time Tradeoff. <i>Medical Decision Making</i> , 2016, 36, 187-198.	2.4	11
23	Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 857-873.	2.1	11
24	Measurement and evaluation of quality of life and well-being in individuals having or having had fertility problems: a systematic review. <i>European Journal of Contraception and Reproductive Health Care</i> , 2018, 23, 441-450.	1.5	10
25	New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year. <i>European Journal of Health Economics</i> , 2018, 19, 277-291.	2.8	9
26	Healthcare utilization and costs of multiple sclerosis patients in the Netherlands: a healthcare claims database study. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 453-462.	1.4	7
27	Health state utilities for infertility and subfertility. <i>Reproductive Health</i> , 2019, 16, 47.	3.1	6
28	Direct and Indirect Cost of Beta Thalassemia Major: Results from the ITHACA Study.. <i>Blood</i> , 2006, 108, 3343-3343.	1.4	2
29	A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 93-100.	1.4	0